| Dr Christopher Hoover Smith, PHD | |
|
1700 Geary St Se, Albany, OR 97322-6842 | |
| (541) 812-5570 | |
| Not Available |
| Full Name | Dr Christopher Hoover Smith |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 12 Years |
| Location | 1700 Geary St Se, Albany, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922377233 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 2301 (Oregon) | Primary |
| Entity Name | Albany General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154372340 PECOS PAC ID: 9931097987 Enrollment ID: O20040310000310 |
News Archive
New research published by the Neuronal Mechanism for Critical Period Unit at the Okinawa Institute of Science and Technology Graduate University has shown the effectiveness of chemogenetic inhibition used to suppress neuronal activity as well as interesting results on how vocalization is controlled through this techniques application in zebra finches.
Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients - challenges which are best addressed through collaboration in international networks.
Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.
Researchers from the University of Liverpool have identified a new compound that protects against neurodegeneration in nematode worms. The discovery may enable novel treatments for human neurodegenerative diseases to be developed in the future.
› Verified 7 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20061104000117 |
News Archive
New research published by the Neuronal Mechanism for Critical Period Unit at the Okinawa Institute of Science and Technology Graduate University has shown the effectiveness of chemogenetic inhibition used to suppress neuronal activity as well as interesting results on how vocalization is controlled through this techniques application in zebra finches.
Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients - challenges which are best addressed through collaboration in international networks.
Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.
Researchers from the University of Liverpool have identified a new compound that protects against neurodegeneration in nematode worms. The discovery may enable novel treatments for human neurodegenerative diseases to be developed in the future.
› Verified 7 days ago
| Entity Name | Conifer Wellness, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912551771 PECOS PAC ID: 3971916537 Enrollment ID: O20201229001361 |
News Archive
New research published by the Neuronal Mechanism for Critical Period Unit at the Okinawa Institute of Science and Technology Graduate University has shown the effectiveness of chemogenetic inhibition used to suppress neuronal activity as well as interesting results on how vocalization is controlled through this techniques application in zebra finches.
Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients - challenges which are best addressed through collaboration in international networks.
Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.
Researchers from the University of Liverpool have identified a new compound that protects against neurodegeneration in nematode worms. The discovery may enable novel treatments for human neurodegenerative diseases to be developed in the future.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Hoover Smith, PHD 1700 Geary St Se, Albany, OR 97322-6842 Ph: (541) 812-5570 | Dr Christopher Hoover Smith, PHD 1700 Geary St Se, Albany, OR 97322-6842 Ph: (541) 812-5570 |
News Archive
New research published by the Neuronal Mechanism for Critical Period Unit at the Okinawa Institute of Science and Technology Graduate University has shown the effectiveness of chemogenetic inhibition used to suppress neuronal activity as well as interesting results on how vocalization is controlled through this techniques application in zebra finches.
Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients - challenges which are best addressed through collaboration in international networks.
Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.
Researchers from the University of Liverpool have identified a new compound that protects against neurodegeneration in nematode worms. The discovery may enable novel treatments for human neurodegenerative diseases to be developed in the future.
› Verified 7 days ago
Linda Renee Bockheim, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 425 2nd Ave Sw Ste 204, Albany, OR 97321 Phone: 541-248-9153 | |
Amy Leroy, PHD Psychologist Medicare: Medicare Enrolled Practice Location: 534 Pleasant View Way Nw Ste 200, Albany, OR 97321 Phone: 541-812-5760 | |
Alexandra Lee Koenig, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1700 Geary St Se Ste 200, Albany, OR 97322 Phone: 541-812-5570 | |
Michael Boggess, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 534 Pleasant View Way Nw Ste 300, Albany, OR 97321 Phone: 541-812-3323 | |
Ms. Ann Marie Meadowbrook, MS Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1052 Sw 29th, Albany, OR 97321 Phone: 541-926-8288 Fax: 541-926-7234 | |
Dr. Jane Irby Allen, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 445 3rd Ave Sw, Albany, OR 97321 Phone: 541-967-3866 | |
Sergio Alejandro Sanchez Carrasco, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 445 3rd Ave Sw, Albany, OR 97321 Phone: 541-967-3866 |